Tempest Therapeutics Says Justin Trojanowski To Resign As Principal Financial Officer Effective Sept 1; Nicholas Rossettos Appointed As CFO, Principal Financial Officer
-SEC Filing
Stocks · News reference
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Tempest Therapeutics, Inc. (TPST)
Filed: 2026-08-24 AccNo: 0001193125-26-363695 Size: 177 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Tempest Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 8,910,579 Shares Of Common Stock
-SEC Filing
Tempest Therapeutics shares are trading lower after the company reported worse-than-expected Q2 EPS results.